|1.||Wong, Tai W: 2 articles (09/2008 - 10/2006)|
|2.||Armand, J-P: 1 article (02/2012)|
|3.||Martell, R E: 1 article (02/2012)|
|4.||Massard, C: 1 article (02/2012)|
|5.||Soria, J-C: 1 article (02/2012)|
|6.||Baselga, J: 1 article (02/2012)|
|7.||Lopez, E: 1 article (02/2012)|
|8.||De Andreis, D: 1 article (02/2012)|
|9.||Marier, J-F: 1 article (02/2012)|
|10.||Beliveau, M: 1 article (02/2012)|
02/01/2012 - "BMS-599626 was generally well tolerated, with disease stabilization across a range of tumor types and doses."
10/15/2006 - "The preclinical data support the advancement of BMS-599626 into clinical development for the treatment of cancer."
10/15/2006 - "BMS-599626 inhibits HER1/HER2 receptor heterodimerization and provides an additional mechanism of inhibiting tumors in which receptor coexpression and heterodimerization play a major role in driving tumor growth. "
10/15/2006 - "In tumor cells that are capable of forming HER1/HER2 heterodimers, BMS-599626 inhibited heterodimerization and downstream signaling. "
10/15/2006 - "BMS-599626 was highly selective for tumor cells that depend on HER1/HER2 and had no effect on the proliferation of cell lines that do not express these receptors. "
|2.||Ovarian Neoplasms (Ovarian Cancer)
|3.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
|1.||Epidermal Growth Factor Receptor (EGF Receptor)
|3.||tyrosine receptor (receptor, tyrosine)
|1.||Heterologous Transplantation (Xenotransplantation)